Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman w

[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, t

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and pr

Instead, it's -- of all things -- a medical diagnostics company. In this niche, the company has seve

UBS analyst Doug Schenkel maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target f

Rothschild & Co analyst Jamie Clark initiates coverage on Natera (NASDAQ:NTRA) with a Buy rat

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.54% on an annualized b

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced

Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC.

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.63% on an annualized b

Citigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price ta

Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:NTRA) with a Overweight and raise

Stephens & Co. analyst Mason Carrico maintains Natera (NASDAQ:NTRA) with a Overweight and rai

Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:NTRA) with a Buy and raises the price tar

Phase I trial in Germany will support treatment response monitoring for Kupando Therapeutics’ invest

TD Cowen analyst Dan Brennan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price targe

Citigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price ta

RBC Capital analyst Dan Leonard maintains Natera (NASDAQ:NTRA) with a Outperform and raises the p

U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 result

Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue out

JP Morgan analyst Casey Woodring maintains Natera (NASDAQ:NTRA) with a Overweight and raises the

Wells Fargo analyst Evan Stampler maintains Natera (NASDAQ:NTRA) with a Equal-Weight and raises t

Evercore ISI Group analyst Daniel Markowitz maintains Natera (NASDAQ:NTRA) with a Outperform and

Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The

BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target f

Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market

Natera (NASDAQ:NTRA) raises FY2026 sales outlook from $2.740 billion-$2.820 billion to $2.850 billio

Natera (NASDAQ:NTRA) reported quarterly losses of $(0.47) per share which beat the analyst consensus

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 24.85% on an annualized b

The submission advances Natera’s growing presence in Japan, where Signatera received PMDA approval i

The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), f

Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full de

Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and raises the pr

Morgan Stanley analyst Tejas Savant maintains Natera (NASDAQ:NTRA) with a Overweight and raises t

Evercore ISI Group analyst Daniel Markowitz maintains Natera (NASDAQ:NTRA) with a Outperform and

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced

Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:NTRA) with a Buy and raises the price tar

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomi

Bernstein analyst Eve Burstein reiterates Natera (NASDAQ:NTRA) with a Outperform and announces $310

Eledon has established the regulatory framework for its Phase 3 kidney transplantation program and p

Natera won Japan approval for Signatera in colorectal cancer, paving the way for a commercial launch

BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target f

Barclays analyst Luke Sergott maintains Natera (NASDAQ:NTRA) with a Overweight and lowers the pri

BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target f

Natera (NTRA) stock rallies following a key NCCN guideline update for Signatera. Also, check out the

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced

RBC Capital analyst Dan Leonard reinstates Natera (NASDAQ:NTRA) with a Outperform and announces $

Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets

Goldman Sachs analyst Evie Koslosky initiates coverage on Natera (NASDAQ:NTRA) with a Neutral rat